Neurocrine Biosciences: Buy Rated As Q3 2025 Earnings Catalyst Approaches

Neurocrine Biosciences shows strong growth with rising INGREZZA sales, expanding pipeline, and solid financials despite key ...
abc27

Neurocrine Biosciences Presents New Post-Hoc Analysis: Treatment with INGREZZA® (valbenazine) Capsules Achieves Earlier Remission of Tardive Dyskinesia Symptoms While Reducing ...

The KINECT-PRO™ analysis is the first and only of its kind to report both remission of tardive dyskinesia symptoms and associated improvements in patient-reported outcomes. Post-hoc analysis from ...
Seeking Alpha

Neurocrine Biosciences targets $2.5B-$2.6B INGREZZA sales for 2025 amid expanded sales force

CEO Kyle Gano highlighted Neurocrine's transformation into a fully integrated biopharmaceutical company. He emphasized the strong performance of INGREZZA, which is poised for double-digit ...
Nasdaq

Neurocrine Biosciences Announces FDA Approval of INGREZZA® (valbenazine) Capsules for the Treatment of Chorea Associated With Huntington's Disease

SAN DIEGO, Aug. 18, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration (FDA) has approved INGREZZA® (valbenazine) capsules for the ...
Business Insider

Neurocrine Biosciences Reports Third Quarter 2022 Financial Results and Raises 2022 INGREZZA Sales Guidance

INGREZZA ® (valbenazine) Third Quarter Net Product Sales of $376 Million INGREZZA ® (valbenazine) 2022 Net Product Sales Guidance Raised to $1.4 - $1.425 Billion Supplemental New Drug Application ...
WebMD

How Ingrezza Works for Tardive Dyskinesia and Chorea

People with movement disorders can have a difficult time doing day-to-day activities, which could impact their independence. This can affect how people see themselves and affect their social life.
Business Insider

Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2021 Financial Results and Provides Financial Expectations for Fiscal 2022

SAN DIEGO, Feb. 11, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the fourth quarter and fiscal year ended December 31, 2021 and provided ...